Zhang Lin, Mai Wuqian, Jiang Wenyang, Geng Qing
Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2020 Nov 26;10:594558. doi: 10.3389/fonc.2020.594558. eCollection 2020.
Sintilimab (Tyvyt) is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approved to treat relapsed or refractory classical Hodgkin lymphoma in patients who have undergone two or more lines of systemic chemotherapy by the National Medical Products Administration of China. Recently, sintilimab has been reported in plenty of literature and shows satisfying anti-tumor effect. Meanwhile, there are some reports showing its side effects. Overall, sintilimab has similar anti-tumor effects and a better safety profile compared to nivolumab and pembrolizumab in Hodgkin lymphoma, natural killer/T cell lymphoma and advanced non-small cell lung cancer. In this review, we aim to briefly describe the mechanisms, pharmacological characteristics, anti-tumor effects, predictive parameters of efficacy and side effects of sintilimab, providing valuable information of sintilimab for decision-making in the treatment of tumors in the future.
信迪利单抗（达伯舒）是一种抗程序性细胞死亡蛋白1（PD-1）的单克隆抗体。它可以阻断PD-1与其配体之间的相互作用，并有助于恢复T细胞的抗肿瘤作用。信迪利单抗由信达生物制药集团和礼来公司联合开发，已被中国国家药品监督管理局批准用于治疗接受过二线及以上全身化疗的复发或难治性经典型霍奇金淋巴瘤患者。最近，信迪利单抗在大量文献中被报道，并显示出令人满意的抗肿瘤效果。同时，也有一些报告显示了其副作用。总体而言，在霍奇金淋巴瘤、自然杀伤/T细胞淋巴瘤和晚期非小细胞肺癌中，信迪利单抗与纳武利尤单抗和帕博利珠单抗相比具有相似的抗肿瘤效果和更好的安全性。在本综述中，我们旨在简要描述信迪利单抗的作用机制、药理特性、抗肿瘤作用、疗效预测参数和副作用，为未来肿瘤治疗决策提供有关信迪利单抗的有价值信息。
